{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:23:40Z","timestamp":1793334220933,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premenopausal, high-risk, hormone receptor-positive breast cancer patients are often treated with ovarian suppression in combination with aromatase inhibitors (AI). This combination has important adverse effects, particularly in sexual function, such as vaginal dryness and loss of libido. There is no effective therapy for reduced sexual function in this setting. Our study aimed to determine the efficacy and safety, particularly regarding sexual function, of a low-dose, topical testosterone gel administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a pilot, single-center study, designed to evaluate the efficacy of topical testosterone gel (3\u00a0mg\/day) in improving sexual function in 29 premenopausal patients on ovarian suppression in combination with an AI. The primary safety endpoint was to assess serum estradiol elevation. The primary efficacy endpoint was sexual function improvement, assessed by the Female Sexual Function Index questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We report the results on 29 patients. Twenty-two patients (75%) completed the 3-month treatment, and seven discontinued treatment before completion, mostly due to logistical difficulties related to the COVID-19 pandemic. All patients maintained the value of baseline mass spectrometry assay for estradiol of less than 2.7 pg\/mL during the undertaken measurements. We observed a significant improvement in\n                      <jats:italic>Female Sexual Function Index<\/jats:italic>\n                      measures over the visits, with an increase from a mean of 11.7 at baseline to 19.1 in the third month (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the greatest improvement observed between the second and third months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that topical testosterone seems to be safe and may be effective in improving sexual function in patients on ovarian suppression and AI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The project was submitted and approved through the hospital\u2019s SGPP platform in 11\/26\/2019 (Project No. SGPP 393819) and CAAE (Research Ethics Committee) (CAAE No 25609719.5.0000.007).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-024-01886-7","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:02:45Z","timestamp":1726462965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Patr\u00edcia","family":"Taranto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"de Brito Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Cotait","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Aliosha Kaliks","family":"Guendelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"de Melo Pompei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Carlos","family":"Buzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Schvartsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"3","key":"1886_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"2","key":"1886_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107\u201318.","journal-title":"N Engl J Med"},{"key":"1886_CR3","doi-asserted-by":"crossref","unstructured":"Gray R, Francis BR, Regan P. M, Effects of ovarian or suppression on breast cancer recurrence and survival: patient-level meta-analyses of 14,999 pre-menopausal woman in 25 randomized trials. 2023 ASCO Annual Meeting. Oral Abstract Session.","DOI":"10.1200\/JCO.2023.41.16_suppl.503"},{"issue":"21","key":"1886_CR4","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004;22(21):4261\u201371.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1886_CR5","first-page":"CD013538","volume":"3","author":"KT Bui","year":"2020","unstructured":"Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. 2020;3(3):CD013538.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1886_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","volume":"3","author":"ME Melisko","year":"2017","unstructured":"Melisko ME, Goldman ME, Hwang J, Luca A, Fang S, Esserman LJ, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313\u20139.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1886_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","volume":"16","author":"S Witherby","year":"2011","unstructured":"Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study. Oncologist. 2011;16(4):424\u201331.","journal-title":"Oncologist"},{"issue":"12","key":"1886_CR8","doi-asserted-by":"publisher","first-page":"e1846","DOI":"10.1634\/theoncologist.2020-0417","volume":"25","author":"P S\u00e1nchez-Rovira","year":"2020","unstructured":"S\u00e1nchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C. A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846\u201354.","journal-title":"Oncologist"},{"issue":"8","key":"1886_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.steroids.2007.05.003","volume":"72","author":"RJ Santen","year":"2007","unstructured":"Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, et al. Superiority of gas chromatography\/tandem mass spectrometry assay (GC\/MS\/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007;72(8):666\u201371.","journal-title":"Steroids"},{"issue":"10204","key":"1886_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159\u201368.","journal-title":"Lancet"},{"issue":"1","key":"1886_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1186\/s12885-019-6457-8","volume":"19","author":"RL Glaser","year":"2019","unstructured":"Glaser RL, York AE, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. 2019;19(1):1271.","journal-title":"BMC Cancer"},{"issue":"9407","key":"1886_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","volume":"363","author":"L Holmberg","year":"2004","unstructured":"Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453\u20135.","journal-title":"Lancet"},{"issue":"2","key":"1886_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/02841860601034834","volume":"46","author":"LE Rutqvist","year":"2007","unstructured":"Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46(2):133\u201345.","journal-title":"Acta Oncol"},{"issue":"2","key":"1886_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, LIBERATE Study Group, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135\u201346.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1886_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1886_CR16","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1590\/S0102-311X2009001100004","volume":"25","author":"RC Pacagnella","year":"2009","unstructured":"Pacagnella RC, Martinez EZ, Vieira EM. [Construct validity of a Portuguese version of the female sexual function index]. Cad Saude Publica. 2009;25(11):2333\u201344. Portuguese.","journal-title":"Cad Saude Publica"},{"key":"1886_CR17","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG. Practical statistics for medical research. London: Chapman & Hall\/CRC; 1991."},{"key":"1886_CR18","volume-title":"Extending the linear model with R: generalized linear, mixed effects and nonparametric regression models","author":"JJ Faraway","year":"2006","unstructured":"Faraway JJ. Extending the linear model with R: generalized linear, mixed effects and nonparametric regression models. Boca Raton: Chapman & Hall\/CRC; 2006."},{"issue":"2","key":"1886_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1590\/S0102-311X2008000200021","volume":"24","author":"RC Pacagnella","year":"2008","unstructured":"Pacagnella RC, Vieira EM, Rodrigues Junior OM, Souza C. [Cross-cultural adaptation of the female sexual function index]. Cad Saude Publica. 2008;24(2):416\u201326. Portuguese.","journal-title":"Cad Saude Publica"},{"issue":"3","key":"1886_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.maturitas.2015.06.002","volume":"82","author":"R Glaser","year":"2015","unstructured":"Glaser R, Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas. 2015;82(3):291\u20135.","journal-title":"Maturitas"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01886-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:33:12Z","timestamp":1726648392000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01886-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01886-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4325612\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the hospital\u2019s SGPP platform in 11\/26\/2019 (Project No. SGPP: 3938-19) and CAAE (Research Ethics Committee) (CAAE No: 25609719.5.0000.007). All patients were informed in writing and following oral consultation. All patients have provided written consent before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}